Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial of CMND-100 for Alcoh | May 26, 2026 |
| APLS | 15-12G | neutral | 6/10 | Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective | May 26, 2026 |
| EDIT | 8-K | bullish | 5/10 | Editas Medicine suspended and terminated the prospectus supplement under its at-the-market (ATM) offering agreement with | May 26, 2026 |
| CGON | 8-K | neutral | 3/10 | CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur | May 26, 2026 |
| CYPH | 8-K | neutral | 3/10 | Cypherpunk Technologies received a Nasdaq notice on May 21, 2026, confirming it has regained compliance with the minimum | May 26, 2026 |
| KZIA | 6-K | bullish | 5/10 | Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 to 36 patients follow | May 26, 2026 |
| MBRX | 8-K | neutral | 3/10 | Moleculin Biotech furnished a corporate investor presentation via an 8-K (Item 7.01). No new financial data, guidance, o | May 26, 2026 |
| SXTP | PRESS-RELEASE | neutral | 4/10 | 60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial | May 26, 2026 |
| CLDI | PRESS-RELEASE | neutral | 4/10 | Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) were accepted for publ | May 26, 2026 |
| RYTM | PRESS-RELEASE | neutral | 2/10 | Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthc | May 26, 2026 |
| ESPR | PRESS-RELEASE | neutral | 5/10 | Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid red | May 26, 2026 |
| QUCY | PRESS-RELEASE | bullish | 7/10 | Quantum Cyber announced that all outstanding warrants have been fully exercised, generating over $15 million in gross pr | May 26, 2026 |
| VRAX | 6-K | bullish | 6/10 | Virax Biolabs reported early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infec | May 26, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 6/10 | BriaCell (BCTXL) received a sixth consecutive positive recommendation from the independent DSMB to continue its pivotal | May 26, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca and Daiichi Sankyo announced FDA approval of Datroway (datopotamab deruxtecan) as the first TROP2-directed a | May 26, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP opinion recommending EU approval as a tumor-agnostic m | May 26, 2026 |
| OLMA | 8-K | bullish | 6/10 | Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT | May 26, 2026 |
| OPTHF | 6-K | neutral | 4/10 | Optimi Health Corp. announced completion of a production run of naturally derived psilocybin extract measuring approxima | May 26, 2026 |
| OTLK | PRESS-RELEASE | bullish | 8/10 | Outlook Therapeutics announced that the FDA granted its Formal Dispute Resolution appeal, concluding that substantial ev | May 26, 2026 |
| OLMA | PRESS-RELEASE | neutral | 4/10 | Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination | May 26, 2026 |
| RNAC | PRESS-RELEASE | bullish | 7/10 | Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche | May 26, 2026 |
| RNAZ | DEFA14A | bearish | 6/10 | Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum stockholders' equity re | May 26, 2026 |
| EDIT | 424B5 | bearish | 7/10 | Editas Medicine is conducting a dilutive underwritten public offering of common stock (and/or pre-funded warrants in lie | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warr | May 26, 2026 |
| TKPHF | 6-K | mixed | 6/10 | Takeda filed its Notice of Convocation for the 150th Annual General Meeting of Shareholders, which includes the full FY2 | May 26, 2026 |
| TKPHF | 6-K | neutral | 5/10 | Takeda filed its annual report (FY ended March 31, 2026) via Form 6-K, disclosing total revenue of JPY 4,505,720 million | May 26, 2026 |
| TKPHF | 6-K | mixed | 6/10 | Takeda filed a 6-K containing its executive compensation overview and a shareholder letter from CEO-elect Julie Kim. The | May 26, 2026 |
| ALTO | EFFECT | neutral | 4/10 | Alto Ingredients' shelf registration (S-3, File No. 333-295723) became effective on May 22, 2026, enabling the company t | May 26, 2026 |
| TRIB | EFFECT | bearish | 6/10 | The SEC declared effective Trinity Biotech's F-3 shelf registration (File No. 333-295842) on May 22, 2026, enabling the | May 26, 2026 |
| MIST | EFFECT | bearish | 6/10 | Milestone Pharmaceuticals' $300M universal shelf registration (S-3, File No. 333-295860) became effective on May 22, 202 | May 26, 2026 |